Pharma Friday – September 4, 2026

Published on September 4, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer On August 26, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients […]

The post Pharma Friday – September 4, 2026 appeared first on Endocrine News.

Continue reading on website
Other news

Experts to Debut Society’s Center on Obesity and New Scientific Statement 

September 4, 2026
Members will get a first look at the Society’s new Center on Obesity as well as the Scientific Statement, “Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines,” during a virtual event September 9.  Daniel J. Drucker, MD, a pioneer in the development of GLP-1RA therapies and leader of the writing […]The post Experts to Debut Society’s Center on Obesity and New Scien